Skip to main content
. 2010 Apr 26;3:15–23. doi: 10.2147/idr.s9689

Figure 1.

Figure 1

Percentage of patients (95% CI) achieving HIV RNA < 50 copies/mL.

Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All Rights Reserved.

*P-value derived from a logistic regression model adjusted for baseline HIV RNA level (log10), first enfuvirtide use in optimized background therapy (OBT), first darunavir use in OBT, active protease inhibitors in OBT.